COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

[1]  Junmo Kim,et al.  Fatal Systemic Capillary Leak Syndrome after SARS-CoV-2Vaccination in Patient with Multiple Myeloma , 2021, Emerging infectious diseases.

[2]  G. Arabia,et al.  Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine , 2021, Neurological Sciences.

[3]  John D. Davis,et al.  Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 , 2021, The New England journal of medicine.

[4]  M. Dimopoulos,et al.  The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment , 2021, Blood Cancer Journal.

[5]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[6]  L. Pagano,et al.  COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies , 2021, British journal of haematology.

[7]  F. Rey,et al.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.

[8]  Thomas P. Fabrizio,et al.  Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants , 2021, The New England journal of medicine.

[9]  A. Yılmaz,et al.  Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey , 2021, The Lancet.

[10]  P. Kalra,et al.  Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.

[11]  S. Jagannath,et al.  Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma , 2021, Cancer Cell.

[12]  M. Sadarangani,et al.  Intentions of public school teachers in British Columbia, Canada to receive a COVID-19 vaccine , 2021, Vaccine: X.

[13]  J. Hepojoki,et al.  COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants , 2021, Nature Communications.

[14]  H. Ludwig,et al.  Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience , 2021, HemaSphere.

[15]  H. Schuitemaker,et al.  Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.

[16]  Karen L. Price,et al.  Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. , 2021, JAMA.

[17]  A. Copas,et al.  Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study , 2021, The Lancet Infectious Diseases.

[18]  P. Dormitzer,et al.  BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans , 2021, Nature.

[19]  M. Hassany,et al.  Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. , 2021, JAMA.

[20]  E. Callaway.  Mix-and-match COVID vaccines trigger potent immune response , 2021, Nature.

[21]  P. Khavari,et al.  SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity , 2021, The Lancet Infectious Diseases.

[22]  G. Ciliberto,et al.  Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution , 2021, Journal of Hematology & Oncology.

[23]  K. Watsky,et al.  Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series. , 2021, JAMA dermatology.

[24]  D. Moodley,et al.  Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant , 2021, The New England journal of medicine.

[25]  L. Abu-Raddad,et al.  Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.

[26]  M. Maus,et al.  SARS -CoV-2 T-cell immunity to variants of concern following vaccination , 2021, bioRxiv.

[27]  David A. Drew,et al.  Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study , 2021, The Lancet Infectious Diseases.

[28]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[29]  M. Kaiser,et al.  Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma , 2021, The Lancet Haematology.

[30]  D. Ho,et al.  Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization , 2021, Cell Host & Microbe.

[31]  M. Dimopoulos,et al.  Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose , 2021, Blood.

[32]  J. Bussel,et al.  SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia , 2021, The New England journal of medicine.

[33]  D. Goldblatt,et al.  Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.

[34]  Andreas Greinacher,et al.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.

[35]  A. Kenig,et al.  Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products , 2021, Clinical Immunology.

[36]  J. Mascola,et al.  Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 , 2021, The New England journal of medicine.

[37]  anonymous.  An EUA for bamlanivimab and etesevimab for COVID-19. , 2021, The Medical letter on drugs and therapeutics.

[38]  A. Hurt,et al.  Neutralizing Antibody Therapeutics for COVID-19 , 2021, Viruses.

[39]  J. Wrammert,et al.  Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant , 2021, Cell Host & Microbe.

[40]  S. Madhi,et al.  Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant , 2021, The New England Journal of Medicine.

[41]  N. G. Davies,et al.  Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.

[42]  William T. Harvey,et al.  Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.

[43]  V. Simon,et al.  Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine , 2021, The New England journal of medicine.

[44]  M. Landray,et al.  Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[45]  P. Dormitzer,et al.  Neutralizing Activity of BNT162b2-Elicited Serum , 2021, The New England journal of medicine.

[46]  V. Gushchin,et al.  Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia , 2021, The Lancet.

[47]  Elisabeth Mahase.  Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant , 2021, BMJ.

[48]  J. Gunst,et al.  SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses , 2021, EBioMedicine.

[49]  F. Polack,et al.  Prevention of severe COVID-19 in the elderly by early high-titer plasma therapy , 2021, The New England Journal of Medicine.

[50]  Paige G. Wickner,et al.  mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[51]  E. Phillips,et al.  Maintaining Safety with SARS-CoV-2 Vaccines , 2020, The New England journal of medicine.

[52]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[53]  John D. Davis,et al.  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.

[54]  A. Iafrate,et al.  COVID-19-neutralizing antibodies predict disease severity and survival , 2020, Cell.

[55]  Ping Li,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .

[56]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[57]  J. Mascola,et al.  Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.

[58]  H. Einsele,et al.  Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set , 2020, Blood.

[59]  W. Wood,et al.  Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients , 2020, Blood.

[60]  A. Iafrate,et al.  COVID-19 neutralizing antibodies predict disease severity and survival , 2020, medRxiv.

[61]  H. Larson,et al.  Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study , 2020, The Lancet.

[62]  G. Morgan,et al.  COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers , 2020, Blood cancer discovery.

[63]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[64]  S. Jagannath,et al.  A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward , 2020, Journal of Hematology & Oncology.

[65]  J. San-Miguel,et al.  Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality , 2020, Blood Cancer Journal.

[66]  M. Koopmans,et al.  Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients , 2020, Haematologica.

[67]  M. Jenner,et al.  Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy , 2020, British journal of haematology.

[68]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[69]  C. Weyand,et al.  Influence of immune aging on vaccine responses , 2020, Journal of Allergy and Clinical Immunology.

[70]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[71]  G. Gahrton,et al.  Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma , 2019, PloS one.

[72]  T. Bamdad,et al.  Lenalidomide acts as an adjuvant for HCV DNA vaccine , 2017, International immunopharmacology.

[73]  R. Greil,et al.  T cells in multiple myeloma display features of exhaustion and senescence at the tumor site , 2016, Journal of Hematology & Oncology.

[74]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[75]  N. Nassif,et al.  Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade , 2016, Leukemia.

[76]  U. Mellqvist,et al.  Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients , 2015, Haematologica.

[77]  U. Mellqvist,et al.  Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study , 2012, Haematologica.

[78]  C. Huff,et al.  Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses , 2012, Clinical Cancer Research.

[79]  C. Wennerås,et al.  Comparative Study of Immune Status to Infectious Agents in Elderly Patients with Multiple Myeloma, Waldenstrom's Macroglobulinemia, and Monoclonal Gammopathy of Undetermined Significance , 2011, Clinical and Vaccine Immunology.

[80]  Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings , 2020 .

[81]  K. McCullough,et al.  Self-Replicating RNA Vaccine Delivery to Dendritic Cells. , 2017, Methods in molecular biology.